← Leaderboards
Jessica E Thaxton
Univ Of North Carolina Chapel Hill
$4,123,586
Attributed
$4,123,586
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $781.4K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,123,586 · 3
By mechanism
R01$4,123,586 · 3
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Benjamin D Philpot$13,874,681
- Julie L Daniels$25,537,385
- Aysenil Belger$18,594,352
- Mark J Zylka$33,948,391
- Amanda E Nelson$9,806,242
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorResponseCancer PatientCd8b1 GeneStressImmunotherapyT-LymphocyteSarcomaMolecular TargetMetabolicSolid NeoplasmSensorShapesGeneticCellsPhosphotransferasesMolecularCell PhysiologyMetabolomicsEndoplasmic ReticulumEndoplasmic Reticulum StressChronicAcuteBiological Adaptation To Stress
Grant awards (14)
Manipulating Lipid Metabolism to Reverse Immune Dysfunction in Solid Cancers$496,391
R01 · FY2025 · CA · contact PI
Expoitation of ER Stress Induced Immune Dysfunction to Improve Immunotherapy$335,255
R01 · FY2024 · CA · contact PI
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy$332,665
R01 · FY2024 · CA · contact PI
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy$82,870
R01 · FY2024 · CA · contact PI
Expoitation of ER Stress Induced Immune Dysfunction to Improve Immunotherapy$348,592
R01 · FY2023 · CA · contact PI
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy$345,558
R01 · FY2023 · CA · contact PI
ATF4 As A Driver of T Cell Inefficacy in Tumors$87,216
R01 · FY2023 · CA · contact PI
Expoitation of ER Stress Induced Immune Dysfunction to Improve Immunotherapy$355,706
R01 · FY2022 · CA · contact PI
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy$349,947
R01 · FY2022 · CA · contact PI
Exploitation of ER Stress Induced Immune Dysfunction to Improve Immunotherapy$341,981
R01 · FY2021 · CA · contact PI
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy$206,758
R01 · FY2021 · CA · contact PI
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy$150,385
R01 · FY2021 · CA · contact PI
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy$348,281
R01 · FY2020 · CA · contact PI
Exploitation of ER Stress Induced Immune Dysfunction to Improve Immunotherapy$341,981
R01 · FY2020 · CA · contact PI